A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.

Trial Details

NCT ID
NCT07117214
Phase
PHASE1
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • [68Ga]Ga-DWJ155
Locations (sample)
  • Groningen, Provincie Groningen, Netherlands|53.21917,6.56667

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Patients with histologically or cytologically confirmed and documented HR+/HER2- advanced breast cancer (aBC), advanced defined as locoregionally a…
  • Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional CT scan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →